Ischemic heart disease in type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 52, Issue 8 SUPPL. 1, 2003, Pages 6-12

  Otel, Irina ^a   Ledru, François ^a   Danchin, Nicolas ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROPAMIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FENOFIBRATE; FIBRINOGEN RECEPTOR ANTAGONIST; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; METFORMIN; NICORANDIL; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; POTASSIUM CHANNEL; RAMIPRIL; RAPAMYCIN; STREPTOKINASE; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORNEA SURGERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INSULIN TREATMENT; INTENSIVE CARE; ISCHEMIC HEART DISEASE; LIFESTYLE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SILENT MYOCARDIAL ISCHEMIA;

EID: 0041384569     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00216-6     Document Type: Article

References (58)

1. Danchin N, Hanania G, Grenier O, et al: Evolution du traitement de sortie après hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000: Données des études USIK 1995, Prévenir 1 et 2 et USIC 2000. Ann Cardiol Angeiol 52:1-6, 2003
2. Hasdai D, Behar S, Wallentin L, et al: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of acute coronary syndromes (Euro Heart Survey ACS). Eur Heart J 23:1190-1121, 2002
3. Ledru F, Ducimetiète P, Battaglia S, et al: New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol 37:1543-1550, 2001
4. Henry P, Makowski S, Richard P, et al: Increased incidence of moderate stenosis among patients with diabetes: Substrate for myocardial infarction? Am Heart J 134:1037-1043, 1997
5. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
6. Wilson PW, D'Agostino RB, Sullivan L, et al: CHD risk in persons with diabetes mellitus or with known coronary heart disease. Circulation 106:II-509, 2002 (suppl, abstr 2514)
7. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet 360:7-22, 2002
8. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 26(1):S33-S50, 2003 (suppl 1)
9. Giri S, Shaw LJ, Murthy DR, et al: Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 105:32-40, 2002
10. UK Prospective Diabetes Study (UKPDS) Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS) 38. BMJ 317:713-720, 1998
11. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002
12. Cannon CP on behalf of the CAPRIE Investigators: Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 90:760-762, 2002
13. Steinbuhl SR, Berger PB, Mann JT III, et al: For the CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 288:2411-2420, 2002
14. Freemantle N, Cleland J, Young P, et al: β Blockade after myocardial infarction: Systematic review and meta-regression analysis. BMJ 318:1730-1737, 1999
15. The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
16. Chan AW, Quinn MJ, Bhatt DL, et al: Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 40:669-675, 2002
17. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
18. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996
19. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
20. Serruys PWJC, De Feyter P, Macaya C, et al: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287:3215-3222, 2002
21. Flather MD, Yusuf S, Køber L, et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 355:1575-1581, 2000
22. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
23. Heart Outcome Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and micro-HOPE substudy. Lancet 355:253-259, 2000 diabetes mellitus: Results of the HOPE study and micro-HOPE substudy.
24. Lonn EM, Yusuf S, Dzavik V, et al: Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 103:919-925, 2001
25. Davies RF, Goldberg AD, Forman S, et al: Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95:2037-2043, 1997
26. The BARI Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 35:1122-1129, 2000
27. Weintraub WS, King SB, Douglas JS, et al: Percutaneous transluminal coronary angioplasty as a first revascularization procedure in single-, double-, and triple-vessel coronary artery disease. J Am Coll Cardiol 26:143-151, 1995
28. Sedlis SP, Morrison DA, Lorin JD, et al: Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass. Outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 40:1555-1566, 2002
29. Serruys PW, Unger F, Sousa E, et al: for the Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117-1124, 2001
30. Morice MC, Serruys PW, Sousa EJ, et al, for the RAVEL study Group: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1180, 2002
31. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682, 1993
32. The GUSTO IIb Angioplasty Substudy Investigators: A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336:1621-1628, 1997
33. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001
34. Boersma E, Harrington RA, Moliterno DJ, et al: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 359:189-198, 2002
35. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators: Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354:708-715, 1999
36. Cannon CP, Weintraub WS, Demopoulos LA, et al: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344:1879-1887, 2001
37. Fox KAA, Poole-Wilson PA, Henderson RA, et al, for the RITA investigators: Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Lancet 360:743-751, 2002
38. Seltzer HS: A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21:976-979, 1972
39. ATP channels. Diabetes 47:1412-1418, 1998
40. Gross GJ, Auchampach JA: Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 70:223-233, 1992
41. Engler RL, Yellon DM: Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 94:2297-2301, 1996
42. The IONA Study Group: Effect of nicorandil on coronary events in patients with stable angina: The Impact of Nicorandil in Angina (IONA) randomised trial. Lancet 359:1269-1275, 2002
43. Auchampach JA, Cavero I, Gross GJ: Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 20:765-771, 1992
44. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
45. Gaede P, Vedel P, Larsen N, et al: Multifactorial intervention and cardiovascular risk in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
46. Inagaki N, Gonoi T, Clement JP, et al: A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 16:1011-1017, 1996
47. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes 50:2253-2259, 2001
48. Cleveland JC, Meldrum DR, Cain BS, et al: Oral sulfonylurea hypoglycaemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96:29-32, 1997
49. Klepzig H, Kober G, Matter C, et al: Sulfonylureas and ischaemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20:439-446, 1999
50. ATP channel blockade by glibenclamide on the warm-up phenomenon. Eur Heart J 20:196-202, 1999
51. ATP channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol 79:75-78, 1997
52. ATP channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 23:535-539, 2000
53. Bogaty P, Kingma JG, Robitaille NM, et al: Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina. Relation to myocardial contractility, intensity of exercise and the adenosine triphosphate-sensitive potassium channel. J Am Coll Cardiol 32:1665-1671, 1998
54. Scognamiglio R, Avogaro A, De Kreutzenberg SV, et al: Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51:808-812, 2002
55. Capes SE, Hunt D, Malmberg K, et al: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet 355:773-778, 2000
56. Malmberg K, for the DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314:1512-1515, 1997
57. Garratt KN, Brady PA, Hassinger NL, et al: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124, 1999
58. Jollis JG, Simpson RJ Jr, Cascio WE, et al: Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 138:S376-S380, 1999